Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
61 results
  • Therapeutic outcomes of the LHRH antagonists. [Review]
    Expert Rev Pharmacoecon Outcomes Res 2017; 17(5):481-488Dellis A, Papatsoris A
  • Recently, LHRH antagonists have been established in the management of advanced prostate cancer, although the vast majority of Medical Oncologists and Urologists still prefer the LHRH agonists. Areas Covered: In this article we assess the therapeutic outcomes and the safety of the LHRH antagonists (mainly degarelix) compared to the LHRH agonists. Expert Commentary: Relevant studies demonstrated th…
  • Effects of GnRH antagonists vs agonists in domestic carnivores, a review. [Review]
    Reprod Domest Anim 2012; 47 Suppl 6:373-6Gobello C
  • Gonadotrophin-releasing hormone (GnRH) stimulates the pituitary secretion of both luteinizing and follicle-stimulating hormones, and thus controls the hormonal and reproductive functions of the gonads. GnRH analogs, which include agonists and antagonists, have been produced by amino acid substitutions within the native GnRH molecule resulting in greater potency and a longer duration of effectiven…
  • Androgen deprivation therapy: past, present and future. [Review]
    BJU Int 2012; 109 Suppl 6:1-12Schröder F, Crawford ED, … Keane TE
  • Since Huggins and Hodges demonstrated the responsiveness of prostate cancer to androgen deprivation therapy (ADT), androgen-suppressing strategies have formed the cornerstone of management of advanced prostate cancer. Approaches to ADT have included orchidectomy, oestrogens, luteinizing hormone-releasing hormone (LHRH) agonists, anti-androgens and more recently the gonadotrophin-releasing hormone…
  • Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. [Review]
    Int J Urol 2012; 19(7):594-601Van Poppel H, Klotz L
  • Gonadotropin-releasing hormone agonists and antagonists provide androgen-deprivation therapy for prostate cancer. Unlike agonists, gonadotropin-releasing hormone antagonists have a direct mode of action to block pituitary gonadotropin-releasing hormone receptors. There are two licensed gonadotropin-releasing hormone antagonists, degarelix and abarelix. Of these, degarelix is the more extensively …
  • An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. [Journal Article]
    Ther Adv Urol 2011; 3(3):127-40Boccon-Gibod L, van der Meulen E, Persson BE
  • Androgen deprivation therapy (ADT) is the main treatment approach in advanced prostate cancer and in recent years has primarily involved the use of gonadotropin-releasing hormone (GnRH) agonists. However, despite their efficacy, GnRH agonists have several drawbacks associated with their mode of action. These include an initial testosterone surge and testosterone microsurges on repeat administrati…
New Search Next